A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects.

TQ-B2302 (bevacizumab biosimilar) - Sino Biopharm

Beianting (bevacizumab biosimilar) - Betta Pharma, Chinese PLA General Hospital, Beijing Mabworks Biotech

http://www.ncbi.nlm.nih.gov/pubmed/35961948

Aug 14, 2022